Benjamin R. Yerxa

1.6k total citations
49 papers, 1.3k citations indexed

About

Benjamin R. Yerxa is a scholar working on Physiology, Ophthalmology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Benjamin R. Yerxa has authored 49 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Physiology, 14 papers in Ophthalmology and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Benjamin R. Yerxa's work include Adenosine and Purinergic Signaling (16 papers), Glaucoma and retinal disorders (9 papers) and Ocular Surface and Contact Lens (8 papers). Benjamin R. Yerxa is often cited by papers focused on Adenosine and Purinergic Signaling (16 papers), Glaucoma and retinal disorders (9 papers) and Ocular Surface and Contact Lens (8 papers). Benjamin R. Yerxa collaborates with scholars based in United States, Canada and Spain. Benjamin R. Yerxa's co-authors include Ward Peterson, James G. Douglass, Matthew S. Cowlen, Sammy R. Shaver, R. W. Dougherty, Kunyan Kuang, Jorge Fischbarg, José L. Boyer, William Pendergast and Quan Wen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Benjamin R. Yerxa

49 papers receiving 1.2k citations

Peers

Benjamin R. Yerxa
Benjamin R. Yerxa
Citations per year, relative to Benjamin R. Yerxa Benjamin R. Yerxa (= 1×) peers Assumpta Peral

Countries citing papers authored by Benjamin R. Yerxa

Since Specialization
Citations

This map shows the geographic impact of Benjamin R. Yerxa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin R. Yerxa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin R. Yerxa more than expected).

Fields of papers citing papers by Benjamin R. Yerxa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin R. Yerxa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin R. Yerxa. The network helps show where Benjamin R. Yerxa may publish in the future.

Co-authorship network of co-authors of Benjamin R. Yerxa

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin R. Yerxa. A scholar is included among the top collaborators of Benjamin R. Yerxa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin R. Yerxa. Benjamin R. Yerxa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gum, Glenwood G., et al.. (2017). A 12-Month Study of the ENV515 (Travoprost) Intracameral Implant on Intraocular Pressure in Beagle Dogs. Investigative Ophthalmology & Visual Science. 58(8). 1072–1072. 1 indexed citations
2.
Navrátil, Tomáš, et al.. (2017). Extended PGA Delivery Results in Significant Drug Sparing Compared to Topical PGAs and Achieves Sustained IOP Lowering for 11 Months without Any Loss of Efficacy. Investigative Ophthalmology & Visual Science. 58(8). 2108–2108. 2 indexed citations
3.
Gilger, Brian C., David A. Culp, Craig B Struble, et al.. (2017). Nonclinical Development of ENV905 (Difluprednate) Ophthalmic Implant for the Treatment of Inflammation and Pain Associated with Ocular Surgery. Journal of Ocular Pharmacology and Therapeutics. 34(1-2). 161–169. 8 indexed citations
4.
Owens, Gary, et al.. (2017). Extended release aflibercept with sustained vitreous concentration in non-human primates from biodegradable hydrogel implants. Investigative Ophthalmology & Visual Science. 58(8). 409–409. 1 indexed citations
5.
Williams, Stuart, Kevin P. Herlihy, Gary Owens, et al.. (2015). In-Vitro Release of Bevacizumab from Hydrogel-based Drug Delivery Systems. Investigative Ophthalmology & Visual Science. 56(7). 222–222. 2 indexed citations
6.
Maynor, Benjamin W., et al.. (2014). Precisely Engineered Biodegradable Drug Delivery Systems for the Extended Release of Prostaglandin Analogues in the Anterior Chamber. Investigative Ophthalmology & Visual Science. 55(13). 5268–5268. 1 indexed citations
7.
Williams, Stuart, Kevin P. Herlihy, Gary Owens, et al.. (2014). Photocurable Hydrogel Implants for the Extended Release of Bevacizumab for the Treatment of Age Related Macular Degeneration. Investigative Ophthalmology & Visual Science. 55(13). 471–471. 2 indexed citations
8.
Navrátil, Tomáš, et al.. (2014). Intracameral Conversion of Travoprost to Travoprost Acid in the Normotensive Beagle Dog Model. Investigative Ophthalmology & Visual Science. 55(13). 5270–5270. 2 indexed citations
9.
Maynor, Benjamin W., et al.. (2014). Controlled and Extended Release of Difluprednate from Biodegradable Intraocular Implants Engineered using PRINT® Technology. Investigative Ophthalmology & Visual Science. 55(13). 476–476. 1 indexed citations
10.
Finch, Gregory L., Henry A. Havel, Mostafa Analoui, et al.. (2014). Nanomedicine Drug Development: A Scientific Symposium Entitled “Charting a Roadmap to Commercialization”. The AAPS Journal. 16(4). 698–704. 12 indexed citations
11.
Herlihy, Kevin P., Stuart Williams, Gary Owens, et al.. (2014). Extended Release of Microfabricated Protein Particles from Biodegradable Hydrogel Implants for the Treatment of Age Related Macular Degeneration. Investigative Ophthalmology & Visual Science. 55(13). 1960–1960. 3 indexed citations
12.
Maynor, Benjamin W., et al.. (2013). Precisely Engineered Biodegradable Intraocular Implants for the Sustained Release of Dexamethasone. Investigative Ophthalmology & Visual Science. 54(15). 1079–1079. 1 indexed citations
13.
Morales-Cantón, Virgilio, et al.. (2013). Suprachoroidal Microinjection of Bevacizumab is Well Tolerated in Human Patients. Investigative Ophthalmology & Visual Science. 54(15). 3299–3299. 6 indexed citations
14.
Peral, Assumpta, et al.. (2008). Topical application of nucleotides increase lysozyme levels in tears. SHILAP Revista de lepidopterología. 1 indexed citations
15.
Brubaker, K., Benjamin R. Yerxa, & José L. Boyer. (2006). In vitro Analysis of the Antagonism of the Histamine H1 Receptor by Epinastine: A Kinetic Comparison With Other Marketed Compounds. Investigative Ophthalmology & Visual Science. 47(13). 4975–4975. 3 indexed citations
16.
Kimple, Randall J., Miller B. Jones, Adam Shutes, et al.. (2003). Established and Emerging Fluorescence-Based Assays for G-Protein Function: Heterotrimeric G-Protein Alpha Subunits and Regulator of G-Protein Signaling (RGS) Proteins. Combinatorial Chemistry & High Throughput Screening. 6(4). 399–407. 29 indexed citations
17.
Gukasyan, Hovhannes J., Benjamin R. Yerxa, William Pendergast, & Vincent H.L. Lee. (2002). Metabolism and Transport of Purinergic Receptor Agonists in Rabbit Conjunctival Epithelial Cells. Advances in experimental medicine and biology. 506(Pt A). 255–259. 6 indexed citations
18.
Yerxa, Benjamin R., et al.. (2002). Potency and Duration of Action of Synthetic P2Y2 Receptor Agonists on Schirmer Scores in Rabbits. Advances in experimental medicine and biology. 506(Pt A). 261–265. 17 indexed citations
19.
Yerxa, Benjamin R., Juan Sabater, C. William Davis, et al.. (2002). Pharmacology of INS37217 [P1-(Uridine 5′)-P4- (2′-deoxycytidine 5′)tetraphosphate, Tetrasodium Salt], a Next-Generation P2Y2 Receptor Agonist for the Treatment of Cystic Fibrosis. Journal of Pharmacology and Experimental Therapeutics. 302(3). 871–880. 131 indexed citations
20.
Novack, Gary D., et al.. (2001). Ocular Safety of INS365 Ophthalmic Solution: A P2Y 2 Agonist In Healthy Subjects. Journal of Ocular Pharmacology and Therapeutics. 17(2). 173–179. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026